Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
The purpose of this study is to develop new treatments that will hopefully result in the relief of symptoms and prolongation of life. For this reason, your doctors have offered you treatment with a new experimental drug called PS 341.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Aug 2, 2018 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Rasim Gucalp
- Interventions being studied
- Drug: PS-341 (Velcade-drug)
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
Patients must have confirmed NSCLC (squamous, adeno- and large cell anaplastic carcinoma)stage III B or Stage IV. No prior chemotherapy regimen Patients must have adequate organ and marrow function
Untreated symptomatic brain metastasis Patients with known HIV positivity
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- HealthAlliance HospitalsFitchburg, Massachusetts
- Dartmouth-Hitchcock Medical CenterLebanon, New Hampshire
- Albert Einstein Cancer CenterThe Bronx, New York
- Jacobi Medical CenterThe Bronx, New York
- Montefiore Medical CenterThe Bronx, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 2, 2018. Always confirm current availability with the study team.